By Elise Reuter
Published October 12, 2026
In an industry long dominated by a handful of massive incumbents, the landscape of diabetes management is bracing for a significant disruption. Sava Technologies, a pioneering medtech startup, has officially secured $36 million in a Series B funding round, bringing its total capital raised to $68 million. This influx of investment is not merely a financial milestone; it represents a strategic pivot in the global race to refine continuous glucose monitoring (CGM) technology. By pairing this funding with a landmark exclusive sales agreement with Ascensia Diabetes Care, Sava is signaling its intent to challenge the status quo and push the boundaries of how patients interact with their own biomarkers.
Main Facts: The Sava Proposition
Sava Technologies is positioning itself as a high-tech challenger in the crowded CGM space. While the current market is dominated by two primary manufacturers, Sava aims to differentiate its offering through hardware miniaturization. The company is developing a wearable, continuous glucose sensor that utilizes proprietary "microsensor" technology.
According to technical specifications released by the company, Sava’s sensors are approximately 10 times shorter than the filaments found in existing CGM devices. This reduction in length is intended to minimize skin trauma and physical discomfort, potentially increasing patient compliance—a critical factor in the chronic disease management market.
Beyond hardware, the company’s business model is bolstered by a strategic partnership with Ascensia Diabetes Care. As part of this deal, Ascensia—a global leader in diabetes supplies, including the Contour line of blood glucose meters—has made an equity investment in Sava. This partnership provides Sava with an immediate, robust distribution channel across European markets, bypassing the costly hurdle of building a sales infrastructure from scratch.
Chronology: A Path to Market
The journey for Sava has been one of iterative development and strategic positioning. The following timeline outlines the company’s progression toward commercialization:
- Early Development Phase: Sava focused on the foundational R&D of its miniaturized sensor platform, prioritizing the reduction of insertion pain and the improvement of wearability.
- The Funding Milestones: Following successful seed and Series A rounds, the company achieved its most recent milestone on October 12, 2026, closing a $36 million Series B. This round attracted a diverse group of investors, including Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments, and Pentland Ventures.
- Strategic Alignment (2026): Alongside the funding, the partnership with Ascensia was formalized, integrating Sava into the commercial ecosystem of a major diabetes player.
- Pivotal Trials (2026–2027): Sava has confirmed plans to initiate a pivotal clinical trial within the calendar year. This study is designed to provide the clinical evidence necessary for regulatory filings.
- Regulatory Horizon: The company is targeting a CE mark in the next two years. Upon approval, the device is intended for "non-adjunctive use," meaning patients will be able to make insulin dosing decisions based on sensor readings without the need for routine, painful fingerstick calibrations.
Supporting Data: The Case for Disruption
The demand for CGMs is rapidly outpacing the current supply chain. Despite 12 million people currently utilizing CGMs worldwide, this number represents only a small fraction of the global population living with diabetes.
Market Dynamics and Gaps
Sava’s internal market analysis highlights a critical bottleneck: the "duopoly" problem. With only two major manufacturers controlling the vast majority of the global market, distributors, clinicians, and patients are facing limited choices. Sava’s entry is framed as a necessary diversification of the market, offering a third, technologically distinct alternative.
The Financials
With $68 million raised to date, Sava is well-capitalized to transition from a R&D-focused startup to a commercial entity. The $36 million Series B will be allocated toward:
- Scaling Manufacturing: Transitioning from prototype production to high-volume manufacturing lines that meet medical-grade standards.
- Clinical Validation: Funding the upcoming pivotal trial to ensure safety and accuracy protocols meet the high standards of the CE mark and future FDA requirements.
- Market Readiness: Developing the software and app ecosystem required to process the sensor’s data and provide actionable insights to users.
Official Responses and Strategic Partnerships
The partnership between Sava and Ascensia is a significant vote of confidence in the technology. Ascensia, having previously worked with Senseonics on their long-term implantable sensor, has deep experience in navigating the nuances of the diabetes market.
"The market is growing, but with just two manufacturers leading it, demand is outpacing choice for distributors, clinicians, and patients," a spokesperson for Sava stated during the announcement.
Ascensia’s decision to back Sava is not just a bet on glucose monitoring. The company has explicitly mentioned that Sava’s microsensor technology has long-term potential for tracking biomarkers beyond glucose. This implies a future where the device could evolve into a multi-analyte platform—potentially monitoring lactate, cortisol, or other markers of metabolic health—effectively turning a diabetes management tool into a comprehensive health-tracking wearable.
Meanwhile, Ascensia’s recent move to bring Senseonics’ commercial operations in-house highlights their aggressive strategy to dominate the distribution of next-generation diabetes tech. By holding both a long-term implantable option (via Senseonics) and a user-friendly, non-invasive microsensor (via Sava), Ascensia is building a "best-of-both-worlds" portfolio for clinicians.
Implications: The Future of Diabetes Care
The entry of Sava Technologies into the market carries several profound implications for the medtech sector:
1. Shift Toward "Invisible" Monitoring
As sensors get smaller and less invasive, the stigma associated with diabetes management is likely to decrease. Sava’s 10-fold reduction in filament length is a direct response to the "wearability gap" that prevents many people with Type 2 diabetes from adopting CGM technology.
2. The Rise of the Multi-Biomarker Wearable
The most significant long-term implication is the platform potential. If Sava successfully proves that its microsensors can track more than just glucose, the device could move beyond the diabetes market and into the consumer wellness space. This would place Sava in direct competition with smartwatches and health-tracking wearables, but with the added authority of medical-grade accuracy.
3. Increased Competition and Price Pressure
The introduction of a third major competitor in the CGM space will likely lead to competitive pricing strategies. As manufacturing capacity increases and more players enter the field, the cost of entry for patients could drop, making these devices more accessible to the millions of people who currently rely on outdated, episodic blood glucose testing.
4. Integration into Digital Health Ecosystems
The future of diabetes care is not just about the hardware—it is about the data. Sava’s success will depend on its ability to integrate its data stream into the digital health ecosystems that patients already use. If their sensor data can seamlessly sync with electronic health records (EHR) and existing diabetes management apps, they will have a significant advantage in adoption rates.
Conclusion
As Sava Technologies prepares for its pivotal trial, the medtech world is watching closely. The convergence of new hardware, a strategic partnership with a global distribution giant, and a clear vision for the future of multi-biomarker monitoring puts the company in a strong position. While the road to a CE mark and commercial launch is fraught with regulatory and manufacturing challenges, the company has cleared the most significant hurdle: establishing a viable path to the patient.
For the 12 million people already using CGMs, and the millions more waiting for a better solution, the coming years promise a new era of choice and technological advancement. Sava is not just launching a product; it is challenging the fundamental limitations of current wearable technology, aiming to make health monitoring as unobtrusive as it is essential.
